PUT - SPRINTER OPEN END - ELI LILLY & CO | Delayed Deutsche Boerse AG 02:00:31 22/05/2024 pm IST | ||
| 14.49 EUR | 0.00% |
|
| Current month | -15.56% | ||
| 1 month | -33.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 22/24/22 | 14.49 | 0.00% |
| 21/24/21 | 14.49 | -13.18% |
| 20/24/20 | 16.69 | -5.49% |
| 17/24/17 | 17.66 | +2.61% |
| 16/24/16 | 17.21 | +2.08% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 02:00 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0KJV |
| ISIN | DE000VD0KJV5 |
| Date issued | 19/02/2024 |
| Strike | 961.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 16.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.43 € |
|---|---|
| Lowest since issue | 14.39 € |
| Spread | 0.3 € |
| Spread % | 2.04% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- Certificat